Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thiess Lorenz

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Communications Medicine|May 30, 2026
Health-system barriers and missed opportunities in cardiovascular care in Sierra Leone: a scoping reviewMohamed B Jalloh, Fatima Jalloh, Mamadu Baldeh, et al.
Atherosclerosis|October 8, 2020
Association of high-sensitivity troponin T and I with the severity of stable coronary artery disease in patients with chronic kidney diseaseFabian J Brunner, Friederike Kröger, Christopher Blaum, et al.
Clinical Transplantation|June 9, 2025
Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery DiseaseLukas Köster, Jessica Weimann, Alexander Bernhard, et al.
Atherosclerosis|April 5, 2025
Prognostic utility of high-sensitivity troponins according to atherosclerotic vascular disease severityJulia Rohde, Fabian J Brunner, Alina Goßling, et al.
European Journal of Preventive Cardiology|November 26, 2024
Association of Modifiable Lifestyle Risk Factors with High-Sensitivity Troponin T and I Concentrations and Clinical OutcomesBenjamin Bay, Luise Pieper, Alina Goßling, et al.
Clinical Therapeutics|August 31, 2021
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD CohortChristopher Blaum, Fabian J Brunner, Alina Goßling, et al.
European Journal of Preventive Cardiology|April 10, 2021
Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target populationChristopher Blaum, Fabian J Brunner, Friederike Kröger, et al.
European Journal of Preventive Cardiology|February 13, 2021
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohortChristopher Blaum, Moritz Seiffert, Alina Goßling, et al.
Journal of the American Heart Association|July 21, 2022
Association of High-Sensitivity Troponin T and I Blood Concentrations With All-Cause Mortality and Cardiovascular Outcome in Stable Patients-Results From the INTERCATH CohortBenjamin Bay, Alina Goßling, Christopher M Blaum, et al.
Public Health|November 11, 2025
Telemedicine as a healthcare delivery model for crisis response during the COVID-19 pandemic in NepalArun Gautam, Urza Bhattarai, Sigiriya Aebischer Perone, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Communications Medicine|May 30, 2026
Health-system barriers and missed opportunities in cardiovascular care in Sierra Leone: a scoping reviewMohamed B Jalloh, Fatima Jalloh, Mamadu Baldeh, et al.
Atherosclerosis|October 8, 2020
Association of high-sensitivity troponin T and I with the severity of stable coronary artery disease in patients with chronic kidney diseaseFabian J Brunner, Friederike Kröger, Christopher Blaum, et al.
Clinical Transplantation|June 9, 2025
Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery DiseaseLukas Köster, Jessica Weimann, Alexander Bernhard, et al.
Atherosclerosis|April 5, 2025
Prognostic utility of high-sensitivity troponins according to atherosclerotic vascular disease severityJulia Rohde, Fabian J Brunner, Alina Goßling, et al.
European Journal of Preventive Cardiology|November 26, 2024
Association of Modifiable Lifestyle Risk Factors with High-Sensitivity Troponin T and I Concentrations and Clinical OutcomesBenjamin Bay, Luise Pieper, Alina Goßling, et al.
Clinical Therapeutics|August 31, 2021
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD CohortChristopher Blaum, Fabian J Brunner, Alina Goßling, et al.
European Journal of Preventive Cardiology|April 10, 2021
Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target populationChristopher Blaum, Fabian J Brunner, Friederike Kröger, et al.
European Journal of Preventive Cardiology|February 13, 2021
The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohortChristopher Blaum, Moritz Seiffert, Alina Goßling, et al.
Journal of the American Heart Association|July 21, 2022
Association of High-Sensitivity Troponin T and I Blood Concentrations With All-Cause Mortality and Cardiovascular Outcome in Stable Patients-Results From the INTERCATH CohortBenjamin Bay, Alina Goßling, Christopher M Blaum, et al.
Public Health|November 11, 2025
Telemedicine as a healthcare delivery model for crisis response during the COVID-19 pandemic in NepalArun Gautam, Urza Bhattarai, Sigiriya Aebischer Perone, et al.
Pageof 3